Gu J, He Y, He C, Zhang Q, Huang Q, Bai S
Signal Transduct Target Ther. 2025; 10(1):84.
PMID: 40069202
PMC: 11897415.
DOI: 10.1038/s41392-025-02166-2.
Zhang C, Cui S, Mu J, Liu K, Wang Y, Zhao H
ACS Med Chem Lett. 2025; 16(2):301-310.
PMID: 39967617
PMC: 11831383.
DOI: 10.1021/acsmedchemlett.4c00550.
Pavan M, Menin S, Dodaro A, Novello G, Cavastracci Strascia C, Sturlese M
J Chem Inf Model. 2025; 65(3):1492-1513.
PMID: 39835670
PMC: 11815869.
DOI: 10.1021/acs.jcim.4c01681.
Qian X, Yao M, Xu J, Dong N, Chen S
Front Pharmacol. 2024; 15:1472387.
PMID: 39611175
PMC: 11602306.
DOI: 10.3389/fphar.2024.1472387.
Dernovsek J, Gradisek N, Zajec Z, Urbancic D, Cingl J, Gorican T
RSC Adv. 2024; 14(39):28347-28375.
PMID: 39239280
PMC: 11375794.
DOI: 10.1039/d4ra05878j.
Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer.
Jia L, Yang H, Liu Y, Zhou Y, Li G, Zhou Q
J Nanobiotechnology. 2024; 22(1):198.
PMID: 38649957
PMC: 11036589.
DOI: 10.1186/s12951-024-02460-1.
Intrinsic Solubility of Ionizable Compounds from p Shift.
Preiksa J, Petrikaite V, Petrauskas V, Matulis D
ACS Omega. 2023; 8(47):44571-44577.
PMID: 38046347
PMC: 10688098.
DOI: 10.1021/acsomega.3c04071.
Cascade Transformation of the Ansamycin Benzoquinone Core into Benzoxazole Influencing Anticancer Activity and Selectivity.
Skrzypczak N, Pyta K, Bohusz W, Lesniewska A, Gdaniec M, Ruszkowski P
J Org Chem. 2023; 88(13):9469-9474.
PMID: 37276434
PMC: 10337034.
DOI: 10.1021/acs.joc.3c00493.
The chaperone system in cancer therapies: Hsp90.
Basset C, de Macario E, Leone L, Macario A, Leone A
J Mol Histol. 2023; 54(2):105-118.
PMID: 36933095
PMC: 10079721.
DOI: 10.1007/s10735-023-10119-8.
Impact of Co-chaperones and Posttranslational Modifications Toward Hsp90 Drug Sensitivity.
Backe S, Woodford M, Ahanin E, Sager R, Bourboulia D, Mollapour M
Subcell Biochem. 2022; 101:319-350.
PMID: 36520312
PMC: 10077965.
DOI: 10.1007/978-3-031-14740-1_11.
HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).
Li Z, Luo Y
Oncol Rep. 2022; 49(1).
PMID: 36367182
PMC: 9685368.
DOI: 10.3892/or.2022.8443.
DrugRep: an automatic virtual screening server for drug repurposing.
Gan J, Liu J, Liu Y, Chen S, Dai W, Xiao Z
Acta Pharmacol Sin. 2022; 44(4):888-896.
PMID: 36216900
PMC: 9549438.
DOI: 10.1038/s41401-022-00996-2.
Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy.
Pan X, Mao T, Mai Y, Liang C, Huang W, Rao Y
Molecules. 2022; 27(17).
PMID: 36080326
PMC: 9458065.
DOI: 10.3390/molecules27175561.
The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors.
Basset C, Rappa F, Barone R, Florena A, Porcasi R, de Macario E
Int J Mol Sci. 2022; 23(16).
PMID: 36012578
PMC: 9409185.
DOI: 10.3390/ijms23169317.
Impact of Heat Shock Proteins in Neurodegeneration: Possible Therapeutical Targets.
Beretta G, Shala A
Ann Neurosci. 2022; 29(1):71-82.
PMID: 35875428
PMC: 9305912.
DOI: 10.1177/09727531211070528.
Water Networks Repopulate Protein-Ligand Interfaces with Temperature.
Stachowski T, Vanarotti M, Seetharaman J, Lopez K, Fischer M
Angew Chem Int Ed Engl. 2022; 61(31):e202112919.
PMID: 35648650
PMC: 9329195.
DOI: 10.1002/anie.202112919.
An Insight into the Medicinal Chemistry Perspective of Macrocyclic Derivatives with Antitumor Activity: A Systematic Review.
Liang Y, Fang R, Rao Q
Molecules. 2022; 27(9).
PMID: 35566196
PMC: 9100616.
DOI: 10.3390/molecules27092837.
Dynamics revelation of conformational changes and binding modes of heat shock protein 90 induced by inhibitor associations.
Chen J, Wang J, Lai F, Wang W, Pang L, Zhu W
RSC Adv. 2022; 8(45):25456-25467.
PMID: 35539786
PMC: 9082529.
DOI: 10.1039/c8ra05042b.
Exploring the Prominent and Concealed Inhibitory Features for Cytoplasmic Isoforms of Hsp90 Using QSAR Analysis.
Zaki M, Al-Hussain S, Bukhari S, Masand V, Rathore M, Thakur S
Pharmaceuticals (Basel). 2022; 15(3).
PMID: 35337101
PMC: 8953649.
DOI: 10.3390/ph15030303.
(20S) Ginsenoside Rh2 Exerts Its Anti-Tumor Effect by Disrupting the HSP90A-Cdc37 System in Human Liver Cancer Cells.
Chen C, Wang Y, Zhang E, Li G, Liu W, Li Y
Int J Mol Sci. 2021; 22(23).
PMID: 34884975
PMC: 8658384.
DOI: 10.3390/ijms222313170.
